التفاصيل البيبلوغرافية
| العنوان: |
Durable clinical benefit after dual checkpoint inhibition and single-agent nivolumab following pembrolizumab failure in mismatch repair-deficient colon cancer. |
| المؤلفون: |
Chow, Yat-Fung, Cheng, Hou-Hsuan, Chen, Ming-Huang |
| المصدر: |
Journal of Cancer Research & Practice; Oct-Dec2023, Vol. 10 Issue 4, p146-149, 4p |
| مصطلحات موضوعية: |
IMMUNOTHERAPY, COLON cancer, ENDOMETRIAL cancer, IPILIMUMAB, PEMBROLIZUMAB, DNA mismatch repair |
| مستخلص: |
Immunotherapy with immune checkpoint inhibitors (ICIs) is beneficial in treating tumors with high microsatellite instability or DNA mismatch repair deficiency (dMMR) tumors. However, the ideal therapy for patients with advanced dMMR cancer after the failure of the first ICI regimen remains unclear. This case report describes a patient with dMMR ascending colon cancer who later developed endometrial cancer. The patient underwent a sequence of immunotherapies, starting with pembrolizumab, followed by a combination of ipilimumab and nivolumab and finally single-agent nivolumab. This sequence led to a prolonged period of disease control exceeding 20 months. The case highlights the potential benefits of dual checkpoint inhibition and sequential ICI regimens in managing advanced dMMR tumors even after first-line ICI failure; this combination is a promising strategy to explore in future research. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Cancer Research & Practice is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder